دورية أكاديمية
أعرض في EDS

Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor.

التفاصيل البيبلوغرافية
العنوان: Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor.
المؤلفون: Ducarouge B; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Redavid AR; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Victoor C; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Chira R; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Fonseca A; Research Pathology Department, Centre Léon Bérard, Lyon, France., Hervieu M; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Bergé R; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Lengrand J; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Vieugué P; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Neves D; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Goddard I; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Richaud M; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Laval PA; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Rama N; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Goldschneider D; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Paradisi A; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Gourdin N; Targeting of the Tumor and its Immune Environnement, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France., Chabaud S; UBET, Centre Léon Bérard, Lyon, France., Treilleux I; UBET, Centre Léon Bérard, Lyon, France., Gadot N; Pathology Department, Centre Léon Bérard, Lyon, France., Ray-Coquard I; Pathology Department, Centre Léon Bérard, Lyon, France., Depil S; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France., Decaudin D; Laboratory of Preclinical Investigations, Translational Research Department, Institut Curie, Université Paris-Sciences-et-Lettres, 75005, Paris, France., Némati F; Laboratory of Preclinical Investigations, Translational Research Department, Institut Curie, Université Paris-Sciences-et-Lettres, 75005, Paris, France., Marangoni E; Laboratory of Preclinical Investigations, Translational Research Department, Institut Curie, Université Paris-Sciences-et-Lettres, 75005, Paris, France., Mery-Lamarche E; Department of Pathology, IUCT Oncopole, Toulouse, France., Génestie C; Department of Pathology, Gustave Roussy, Villejuif, France., Tabone-Eglinger S; Pathology Department, Centre Léon Bérard, Lyon, France., Devouassoux-Shisheboran M; Department of Pathology, Hospices Civils de Lyon, 69002, Lyon, France., Moore KJ; Department of Medicine, Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY, USA., Gibert B; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France. benjamin.gibert@lyon.unicancer.fr., Mehlen P; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France. patrick.mehlen@lyon.unicancer.fr.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France. patrick.mehlen@lyon.unicancer.fr., Bernet A; Apoptosis, Cancer and Development Laboratory- Equipe labellisée 'La Ligue', Labex DEVweCAN, Institut Convergence PLAsCAN, Centre de Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Université de Lyon, Centre Léon Bérard, 69008, Lyon, France. agnes.bernet@lyon.unicancer.fr.; Netris Pharma, Centre Léon Bérard, 69008, Lyon, France. agnes.bernet@lyon.unicancer.fr.
المصدر: Cell death and differentiation [Cell Death Differ] 2023 Oct; Vol. 30 (10), pp. 2201-2212. Date of Electronic Publication: 2023 Aug 26.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9437445 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5403 (Electronic) Linking ISSN: 13509047 NLM ISO Abbreviation: Cell Death Differ Subsets: MEDLINE
أسماء مطبوعة: Publication: <2003->: London : Nature Publishing Group
Original Publication: London : Edward Arnold, c1994-
مواضيع طبية MeSH: Netrin-1*/metabolism , Neoplastic Stem Cells*/metabolism , Neoplastic Stem Cells*/drug effects , Neoplastic Stem Cells*/pathology , Myeloid-Derived Suppressor Cells*/metabolism , Myeloid-Derived Suppressor Cells*/drug effects , Drug Resistance, Neoplasm*/drug effects , Immune Checkpoint Inhibitors*/pharmacology , Immune Checkpoint Inhibitors*/therapeutic use, Animals ; Humans ; Mice ; Female ; Cell Line, Tumor ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/metabolism ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Breast Neoplasms/metabolism
مستخلص: Drug resistance and cancer relapse represent significant therapeutic challenges after chemotherapy or immunotherapy, and a major limiting factor for long-term cancer survival. Netrin-1 was initially identified as a neuronal navigation cue but has more recently emerged as an interesting target for cancer therapy, which is currently clinically investigated. We show here that netrin-1 is an independent prognostic marker for clinical progression of breast and ovary cancers. Cancer stem cells (CSCs)/Tumor initiating cells (TICs) are hypothesized to be involved in clinical progression, tumor relapse and resistance. We found a significant correlation between netrin-1 expression and cancer stem cell (CSC) markers levels. We also show in different mice models of resistance to chemotherapies that netrin-1 interference using a therapeutic netrin-1 blocking antibody alleviates resistance to chemotherapy and triggers an efficient delay in tumor relapse and this effect is associated with CSCs loss. We also demonstrate that netrin-1 interference limits tumor resistance to immune checkpoint inhibitor and provide evidence linking this enhanced anti-tumor efficacy to a decreased recruitment of a subtype of myeloid-derived suppressor cells (MDSCs) called polymorphonuclear (PMN)-MDSCs. We have functionally demonstrated that these immune cells promote CSCs features and, consequently, resistance to anti-cancer treatments. Together, these data support the view of both a direct and indirect contribution of netrin-1 to cancer stemness and we propose that this may lead to therapeutic opportunities by combining conventional chemotherapies and immunotherapies with netrin-1 interfering drugs.
(© 2023. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.)
References: Nature. 2023 Aug;620(7973):402-408. (PMID: 37532929)
EMBO Mol Med. 2019 Oct;11(10):e9930. (PMID: 31476112)
Cancer Res. 2019 Jul 15;79(14):3651-3661. (PMID: 31088838)
Tumour Biol. 2016 Nov;37(11):14949-14960. (PMID: 27651158)
Nat Rev Neurosci. 2019 Jul;20(7):380-396. (PMID: 31000796)
Nat Immunol. 2012 Jan 08;13(2):136-43. (PMID: 22231519)
EMBO Mol Med. 2021 Jan 11;13(1):e12798. (PMID: 33283987)
Nat Commun. 2021 Jan 27;12(1):608. (PMID: 33504783)
Sci Signal. 2011 Jan 25;4(157):mr2. (PMID: 21266712)
Hepatology. 2022 Nov;76(5):1345-1359. (PMID: 35253915)
J Natl Cancer Inst. 2014 Oct 13;106(11):. (PMID: 25313246)
J Exp Med. 2009 Apr 13;206(4):833-47. (PMID: 19349462)
Gastroenterology. 2010 Apr;138(4):1595-606, 1606.e1-8. (PMID: 20080097)
Nature. 2001 Nov 1;414(6859):105-11. (PMID: 11689955)
Cancer Res. 2016 Jun 1;76(11):3156-65. (PMID: 27197152)
Clin Cancer Res. 2010 Jan 1;16(1):45-55. (PMID: 20028757)
Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4850-5. (PMID: 18353983)
Semin Immunol. 2018 Feb;35:19-28. (PMID: 29254756)
Nature. 2013 Sep 19;501(7467):346-54. (PMID: 24048067)
J Cardiol. 2014 Feb;63(2):95-8. (PMID: 24262644)
Cancer Cell. 2016 Feb 8;29(2):173-85. (PMID: 26859457)
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82. (PMID: 1359541)
Cancer Res. 2015 Dec 15;75(24):5171-5. (PMID: 26627011)
Nature. 2023 Aug;620(7973):409-416. (PMID: 37532934)
Nat Cell Biol. 2020 Apr;22(4):389-400. (PMID: 32231305)
Nature. 1997 Apr 24;386(6627):796-804. (PMID: 9126737)
Br J Cancer. 2009 Mar 24;100(6):918-22. (PMID: 19240712)
J Natl Cancer Inst. 2009 Feb 18;101(4):237-47. (PMID: 19211441)
J Clin Invest. 2020 Sep 1;130(9):4607-4623. (PMID: 32427586)
Nat Med. 2017 Oct 6;23(10):1124-1134. (PMID: 28985214)
Nat Med. 2014 Apr;20(4):377-84. (PMID: 24584118)
Nat Methods. 2015 Dec;12(12):1143-9. (PMID: 26501517)
Nat Commun. 2015 Jul 08;6:7398. (PMID: 26154507)
Nature. 1997 Apr 24;386(6627):833-8. (PMID: 9126742)
Cancer Res. 2017 Aug 1;77(15):3982-3989. (PMID: 28428275)
Cell Stem Cell. 2007 Nov;1(5):555-67. (PMID: 18371393)
J Immunol. 2016 Aug 15;197(4):1389-98. (PMID: 27430720)
Cell. 2019 May 16;177(5):1172-1186.e14. (PMID: 31031009)
EMBO Mol Med. 2021 Apr 9;13(4):e12878. (PMID: 33719214)
Cell. 1996 Dec 13;87(6):1001-14. (PMID: 8978605)
Oncotarget. 2011 May;2(5):363-7. (PMID: 21789787)
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3722-7. (PMID: 20133591)
EMBO Mol Med. 2023 Apr 11;15(4):e16732. (PMID: 36876343)
J Carcinog. 2019 May 23;18:2. (PMID: 31160888)
EMBO Mol Med. 2013 Dec;5(12):1821-34. (PMID: 24293316)
Cancer Treat Rev. 2018 Feb;63:122-134. (PMID: 29287242)
J Immunol. 2006 Oct 1;177(7):4376-83. (PMID: 16982872)
EMBO Mol Med. 2019 Dec;11(12):e10638. (PMID: 31657150)
Sci Rep. 2021 Feb 18;11(1):4219. (PMID: 33603134)
Nat Rev Cancer. 2011 Mar;11(3):188-97. (PMID: 21326323)
Cancer Med. 2018 Sep;7(9):4509-4516. (PMID: 30039553)
معلومات مُعتمدة: P01 HL131481 United States HL NHLBI NIH HHS
المشرفين على المادة: 158651-98-0 (Netrin-1)
0 (Immune Checkpoint Inhibitors)
0 (NTN1 protein, human)
تواريخ الأحداث: Date Created: 20230826 Date Completed: 20240430 Latest Revision: 20240430
رمز التحديث: 20240501
مُعرف محوري في PubMed: PMC10589209
DOI: 10.1038/s41418-023-01209-x
PMID: 37633969
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5403
DOI:10.1038/s41418-023-01209-x